{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T23:39:55Z","timestamp":1787614795835,"version":"build-2736575974"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T00:00:00Z","timestamp":1761436800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T00:00:00Z","timestamp":1761436800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01394-7","type":"journal-article","created":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T07:53:00Z","timestamp":1761465180000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1922-5157","authenticated-orcid":false,"given":"Calogero","family":"Vetro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Garibaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4365-9406","authenticated-orcid":false,"given":"Francesco","family":"Grimaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1355-1587","authenticated-orcid":false,"given":"Patrizia","family":"Chiusolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Fil\u00ec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carola","family":"Riva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Cardinali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marinunzia","family":"Franciosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Pilo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2855-8121","authenticated-orcid":false,"given":"Raffaele","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Menotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8196-0481","authenticated-orcid":false,"given":"Salvatore","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Mul\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Alati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Vigna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Dargenio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Sperotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Tanasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Papayannidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Molica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Minetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0695-3879","authenticated-orcid":false,"given":"Giorgia","family":"Battipaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Memoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prassede","family":"Salutari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Brunetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Todisco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Lotesoriere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Isidori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Alberto","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Annunziata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Gottardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5256-0726","authenticated-orcid":false,"given":"Massimo","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9139-1729","authenticated-orcid":false,"given":"Maria Paola","family":"Martelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debora","family":"Capelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3987-419X","authenticated-orcid":false,"given":"Massimo","family":"Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicetto","family":"Ferrara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0245-0553","authenticated-orcid":false,"given":"Adriano","family":"Venditti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Romani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Galimberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Candoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luana","family":"Fianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8287-928X","authenticated-orcid":false,"given":"Livio","family":"Pagano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6309-0515","authenticated-orcid":false,"given":"Giovanni","family":"Marconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto Massimo","family":"Lemoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Di Raimondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atto","family":"Billio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4896-6666","authenticated-orcid":false,"given":"Fanny Erika","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Pane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Duminuco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3166-6078","authenticated-orcid":false,"given":"Fabio","family":"Guolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,26]]},"reference":[{"key":"1394_CR1","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1200\/JCO.2010.30.5961","volume":"29","author":"EJ Feldman","year":"2011","unstructured":"Feldman EJ, Lancet JE, Kolitz JE, Ritchie EK, Roboz GJ, List AF, et al. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J Clin Oncol. 2011;29:979\u201385.","journal-title":"J Clin Oncol"},{"key":"1394_CR2","doi-asserted-by":"crossref","unstructured":"Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, et al. Cpx-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018;36:2684\u201392.","DOI":"10.1200\/JCO.2017.77.6112"},{"key":"1394_CR3","doi-asserted-by":"publisher","unstructured":"Guolo F, Fianchi L, Minetto P, Clavio M, Gottardi M, Galimberti S, et al. CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program. Blood Cancer J. 10. https:\/\/doi.org\/10.1038\/s41408-020-00361-8.","DOI":"10.1038\/s41408-020-00361-8"},{"key":"1394_CR4","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1182\/bloodadvances.2020003159","volume":"5","author":"E Chiche","year":"2021","unstructured":"Chiche E, Rahme R, Bertoli S, Dumas PY, Micol JB, Hicheri Y, et al. Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort. Blood Adv. 2021;5:176\u201384.","journal-title":"Blood Adv"},{"key":"1394_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00558-5","volume":"11","author":"C Rautenberg","year":"2021","unstructured":"Rautenberg C, St\u00f6lzel F, R\u00f6llig C, Stelljes M, Gaidzik V, Lauseker M, et al. Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia. Blood Cancer J. 2021;11:164.","journal-title":"Blood Cancer J"},{"key":"1394_CR6","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1111\/bjh.19622","volume":"205","author":"P Mehta","year":"2024","unstructured":"Mehta P, Campbell V, Maddox J, Floisand Y, Kalakonda AJM, O\u2019Nions J, et al. CREST-UK: real-world effectiveness, safety and outpatient delivery of CPX-351 for first-line treatment of newly diagnosed therapy-related AML and AML with myelodysplasia-related changes in the UK. Br J Haematol. 2024;205:1326\u201336.","journal-title":"Br J Haematol"},{"key":"1394_CR7","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.clml.2022.06.001","volume":"22","author":"D Lee","year":"2022","unstructured":"Lee D, Jain AG, Deutsch Y, Eatrides J, Chan O, Padron E, et al. CPX-351 Yields similar response and survival outcome in younger and older patients with secondary acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2022;22:774\u20139.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1394_CR8","doi-asserted-by":"publisher","first-page":"e323","DOI":"10.1016\/j.clml.2023.07.003","volume":"23","author":"A Legg","year":"2023","unstructured":"Legg A, Lambova A, Broe A, Levy J, Medalla G. Real-world experience with CPX-351 treatment for acute myeloid leukemia in England: an analysis from the national cancer registration and analysis service. Clin Lymphoma Myeloma Leuk. 2023;23:e323\u201330.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1394_CR9","doi-asserted-by":"publisher","first-page":"e18530","DOI":"10.1200\/JCO.2019.37.15_suppl.e18530","volume":"37","author":"AC Przespolewski","year":"2019","unstructured":"Przespolewski AC, Talati C, Fazal S, Vachhani P, Sanikommu S, Thota S, et al. Safety and efficacy of CPX-351 in younger patients < 60 years old with secondary acute myeloid leukemia: an updated analysis. J Clin Oncol. 2019;37:e18530.","journal-title":"J Clin Oncol"},{"key":"1394_CR10","doi-asserted-by":"publisher","first-page":"3457","DOI":"10.3390\/cancers15133457","volume":"15","author":"L Fianchi","year":"2023","unstructured":"Fianchi L, Guolo F, Marchesi F, Cattaneo C, Gottardi M, Restuccia F, et al. Multicenter observational retrospective study on febrile events in patients with acute myeloid leukemia treated with Cpx-351 in \u201cReal-Life\u201d: The SEIFEM Experience. Cancers. 2023;15:3457.","journal-title":"Cancers"},{"key":"1394_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01274-0","volume":"15","author":"C Rautenberg","year":"2025","unstructured":"Rautenberg C, Middeke JM, R\u00f6llig C, Stelljes M, Gaidzik V, Kriege O, et al. Real-world experience with first-line CPX-351 treatment in patients with acute myeloid leukemia \u2013 long-term follow-up with focus on younger patients. Blood Cancer J. 2025;15:60.","journal-title":"Blood Cancer J"},{"key":"1394_CR12","doi-asserted-by":"publisher","first-page":"4539","DOI":"10.1182\/bloodadvances.2023010276","volume":"7","author":"J Othman","year":"2023","unstructured":"Othman J, Wilhelm-Benartzi C, Dillon R, Knapper S, Freeman SD, Batten LM, et al. A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial. Blood Adv. 2023;7:4539\u201349.","journal-title":"Blood Adv"},{"key":"1394_CR13","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1182\/bloodadvances.2022007265","volume":"6","author":"AH Matthews","year":"2022","unstructured":"Matthews AH, Perl AE, Luger SM, Loren AW, Gill SI, Porter DL, et al. Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia. Blood Adv. 2022;6:3997\u20134005.","journal-title":"Blood Adv"},{"key":"1394_CR14","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/s41375-024-02175-0","volume":"38","author":"S Shimony","year":"2024","unstructured":"Shimony S, Bewersdorf JP, Shallis RM, Liu Y, Schaefer EJ, Zeidan AM, et al. Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML. Leukemia. 2024;38:762\u20138.","journal-title":"Leukemia"},{"key":"1394_CR15","doi-asserted-by":"publisher","first-page":"e830","DOI":"10.1016\/S2352-3026(24)00241-2","volume":"11","author":"D Russo","year":"2024","unstructured":"Russo D, Polverelli N, Bernardi S, Santarone S, Farina M, Borlenghi E, et al. Venetoclax plus decitabine as a bridge to allogeneic haematopoietic stem-cell transplantation in older patients with acute myeloid leukaemia (VEN-DEC GITMO): final report of a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2024;11:e830\u20138.","journal-title":"Lancet Haematol"}],"updated-by":[{"DOI":"10.1038\/s41408-025-01431-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000}}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01394-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01394-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01394-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:36:03Z","timestamp":1764916563000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01394-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,26]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1394"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01394-7","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,26]]},"assertion":[{"value":"29 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41408-025-01431-5","URL":"https:\/\/doi.org\/10.1038\/s41408-025-01431-5","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.Capelli: Honoraria: Jazz Pharmaceuticals; C.Papayannidis: Honoraria: Abbvie, Astellas, Servier, Menarini\/Stemline, BMS, Pfizer, Amgen, Janssen, Incyte, Novartis, Advisory Board: Pfizer, Astellas, Janssen, GSK, Blueprint, Jazz Pharmaceuticals, Abbvie, Novartis, Delbert Laboratoires; A.Duminuco: Honoraria: Novartis, GSK, Incyte. Support for attending meetings and\/or travel: AbbVie, J&J, AOP Health, Recordati Rare Diseases, BeiOne. Advisory board: Incyte, GSK; M.Rossi: Expert testimony: Abbvie; Astrazeneca. Support for attending meetings and\/or travel: Abbvie; Johnson and Johnson; Amgen; Sobi. Advisory board: Sanofi; Amgen; L.Pagano Grants: Gilead, JAZZ, Menarini-Stemline, Beigene, Blueprint, Pfizer. Honoraria: Gilead, JAZZ, Menarini-Stemline, Beigene, Blueprint, Pfizer. Advisory Board: Pulmocide, Cidara; A.Venditti: Grants or contracts from any entity: Jazz Pharmaceuticals; AstraZeneca; Abbvie. Consulting fees: Jazz Pharmaceuticals; Abbvie; Servier; Istituto Gentili; BMS; Pfizer; Astellas; Otsuka; Janssen; Daiichi-Sankyo. Honoraria: Servier; Jazz Pharmaceuticals; Abbvie; Otsuka; Pfizer; Astellas; Astex; Janssen; Support for attending meetings: Servier; Janssen; Abbvie; Daiichi-Snkyo; Pfizer; Janssen; A.Candoni: honoraria: Astellas, Servier, JAZZ, Incyte, Abbvie; Otsuka; Support for attending meetings and\/or travel: Abbvie, JAZZ, Gilead; L.Brunetti: Honoraria: Jazz Healthcare, Abbvie, Incite, Research support: Karyopharm Therapeutics Inc.; R.M.Lemoli: Travel grant and Speaker\u2019s bureau for Jazz Pharma; F.Guolo: Consultancy: Astellas; JAZZ; P.Minetto: Advisory board: Menarini-Stemline; Abbvie; C.Vetro: Honoraria: JAZZ; Astellas; Advisory Board: JAZZ; Abbvie; BMS; Astellas; Incyte; Amgen; G.Marconi: Honoraria, consulting or advisor from AbbVie Inc, Astellas Pharma, AstraZeneca, Enable life science, ImmunoGen, Janssen, Menarini Group, Pfizer, Ryvu Therapeutics, SERVIER, Syros Pharmaceuticals, Takeda; Speakers\u2019 bureau: AbbVie Inc, Astellas Pharma, AstraZeneca, ImmunoGen, Janssen, Menarini Group, Pfizer, Ryvu Therapeutics, Syros Pharmaceuticals, Takeda; Research funding from AbbVie Inc, Pfizer, Jazz Pharmaceuticals, AstraZeneca, MEI Pharma, and Daiichi Sankyo.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was reviewed and approved by the Institutional review board Catania 1. Mail: celct1@policlinico.unict.it. File number 52\/2021\/PO. Date of approval 22.02.2021.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All procedures were performed in accordance with the Declaration of Helsinki. Informed consent was obtained from all subjects involved in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"181"}}